Muscle AdaptationMyoCreaWalkNCT07891936
Creatine and Muscle Health in Madrid's Walking Footballers.
A study testing Monohydrate Creatine supplementation during Walking Football training in people with Muscle Adaptation and Body Composition, run by Universidad Europea de Madrid.
Trial summary
Healthy aging requires effective, accessible, and sustainable interventions capable of preserving functional capacity and preventing age-related decline. In this context, walking football has emerged as a safe, inclusive physical exercise modality with high adherence among older adults, demonstrating benefits for… Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Muscle Adaptation, Body Composition, Physical Activity in Adults
- What is being tested?
- Monohydrate Creatine supplementation during Walking Football training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2026to Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Individuals over 50 years of age
- Minimum physical activity level recommended by the World Health Organization (≥150 minutes of moderate-intensity activity or ≥75 minutes of vigorous-intensity activity per week)
- Men and women with regular participation (≥2 times per week) in walking football training for at least 6 months
- Voluntary acceptance to participate in the study after having read, understood, and signed the informed consent form.
Who cannot join
- Presence of metabolic, neuromuscular, cardiovascular, or joint diseases that contraindicate moderate-to-vigorous physical activity and/or creatine supplementation
- Current use of creatine nutritional supplements or other ergogenic compounds
- Having any comprehension difficulties or presenting musculoskeletal alterations that influence the assessments
- Being under pharmacological treatment that may alter muscle mass or function
- Cognitive impairment or alteration that prevents following the protocol indications.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effects of Creatine Supplementation on Muscle Health in Madrid's Older Walking Footballers
Healthy aging requires effective, accessible, and sustainable interventions capable of preserving functional capacity and preventing age-related decline. In this context, walking football has emerged as a safe, inclusive physical exercise modality with high adherence among older adults, demonstrating benefits for muscle health, metabolic profile, and psychosocial well-being. On the other hand, creatine monohydrate supplementation is backed by robust scientific evidence as a strategy to enhance exercise adaptations, promote muscle mass maintenance, and improve factors related to metabolic syndrome.
The objective of this project is to evaluate the effects of creatine supplementation combined with regular walking football practice on muscle quality and metabolic profile in older adults, as well as to explore the underlying biological mechanisms using a cell culture-based experimental model. The ultimate goal is to determine the potential of this intervention to promote healthy longevity through functional, muscular, and metabolic indicators associated with healthspan.
Read more
Specifically, the study will analyze the intervention's effects on body composition, physical fitness, and metabolic syndrome markers; evaluate its impact on psychosocial well-being, quality of life, and cognitive function; and investigate the molecular mechanisms related to muscle health, protection against oxidative stress, and the modulation of senescence using an ex vivo/in vitro model.
The project will be carried out in two complementary phases. First, a longitudinal experimental study will be conducted in older adults participating in walking football programs and supplemented with creatine. Subsequently, skeletal muscle cultures will be exposed to conditioned sera obtained before and after the intervention to investigate its biological effects.
This approach will integrate the evaluation of clinical efficacy with the study of the underlying mechanisms, generating applicable knowledge for designing personalized, sustainable, and cost-effective strategies to prevent sarcopenia and metabolic syndrome.
- Being tested
- Monohydrate Creatine supplementation during Walking Football training
- Keywords
- Walking football, Creatine monohydrate, Physical exercise, Sarcopenia, Muscle quality
- Medical subject headings
- Motor Activity, Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Monohydrate Creatine supplementation during Walking Football trainingDietary supplement
Participants will be assessed at baseline, after 16 weeks of supervised Walking Football training, and again after a further 16 weeks of Walking Football combined with daily creatine monohydrate supplementation. This within-subject design allows each participant to serve as their own control when evaluating the effects of creatine supplementation beyond those attributable to Walking Football training alone.
| Study group | Role | What they receive |
|---|---|---|
| Creatine + Walking Football training Group | Experimental | Single-arm, prospective interventional trial with a within-subject (pre-post) design, where each participant serves as his or her own control. Receives: Dietary Supplement: Monohydrate Creatine supplementation during Walking Football training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscle Quality
It is defined as the capacity of skeletal muscle to generate strength relative to its mass, integrating both structural and functional aspects. It will be expressed as the ratio between the estimated 1-RM strength and muscle mass measured by dual-energy X-ray absorptiometry (DEXA)
Measured: From enrollment to the end of treatment at 32 weeks
Secondary outcomes (63)
Nutritional profile
This will be assessed through a nutritional interview conducted by a professional, which will include a complete dietary history, a 24-hour dietary recall (24hR), and a food frequency questionnaire (FFQ)
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
assessed through basic anthropometry: weight in kilogram (kg)
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
assessed through basic anthropometry: height in centimeter (cm)
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
assessed through basic anthropometry: body mass index (BMI), weight and height will be combined to report BMI in kg/m^2
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
Dual X-Ray Densitometry: body adiposity index, (BAI) in perctange (%)
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
Dual X-Ray Densitometry: fat mass index (FMI) kilograms per square meter. kg/m²
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
Dual X-Ray Densitometry: visceral adipose tissue area, VAT Area in square centimeter (cm²)
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
Dual X-Ray Densitometry: skeletal muscle mass index, (SMI) kilograms per square meter. kg/m²
Measured: From enrollment to the end of treatment at 32 weeks
Body composition
Dual X-Ray Densitometry: appendicular skeletal muscle mass index, (ASM). kilograms per square meter. kg/m²
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): VO2 max (L/min) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Relative VO2 (ml/kg/min) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Absolute VO2 (L/min) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Absolute VCO2 (L/min) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Respiratory exchange ratio, RER in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Ventilatory equivalent, rate of ventilation and absolute O2 (VE/O2) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Ventilatory equivalent, rate of ventilation and absolute CO2 (VE/CO2) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
(1) Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): Speed (km/h) in First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
(1) Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): time in sencond (s) when it appears First Ventilatory Threshold, Second Ventilatory Threshold and at maximum test time.
Measured: From enrollment to the end of treatment at 32 weeks
Physical fitness
(1) Cardiorespiratory fitness assessed via a performance test with gas analysis using ergometry (incremental test to exhaustion): V-Slope break-point (%)
Measured: From enrollment to the end of treatment at 32 weeks
Metabolic profile
Clinical and biochemical variables will be included to identify metabolic alterations associated with the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD), based on the criteria proposed by the International Diabetes Federation (IDF): Biochemical variables (fasting): glucose (mg/dL)
Measured: From enrollment to the end of treatment at 32 weeks
Metabolic profile
Clinical and biochemical variables will be included to identify metabolic alterations associated with the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD), based on the criteria proposed by the International Diabetes Federation (IDF): Biochemical variables (fasting): triglycerides (mg/dL)
Measured: From enrollment to the end of treatment at 32 weeks
Metabolic profile
Clinical and biochemical variables will be included to identify metabolic alterations associated with the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD), based on the criteria proposed by the International Diabetes Federation (IDF): Biochemical variables (fasting): total cholesterol (mg/dL)
Measured: From enrollment to the end of treatment at 32 weeks
Metabolic profile
Clinical and biochemical variables will be included to identify metabolic alterations associated with the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD), based on the criteria proposed by the International Diabetes Federation (IDF): Biochemical variables (fasting): HDL-cholesterol (mg/dL)
Measured: From enrollment to the end of treatment at 32 weeks
Metabolic profile
Clinical and biochemical variables will be included to identify metabolic alterations associated with the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD), based on the criteria proposed by the International Diabetes Federation (IDF): Clinical variables: blood pressure (mmHg)
Measured: From enrollment to the end of treatment at 32 weeks
Metabolic profile
Clinical and biochemical variables will be included to identify metabolic alterations associated with the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD), based on the criteria proposed by the International Diabetes Federation (IDF): Clinical variables: waist circumference (cm)
Measured: From enrollment to the end of treatment at 32 weeks
Oxidative status
The following markers will be analyzed using spectrophotometry: malondialdehyde, MDA (µmol/L) (absorbance at 532 nm)
Measured: From enrollment to the end of treatment at 32 weeks
Oxidative status
The following markers will be analyzed using spectrophotometry: glutathione peroxidase, GPX (U/mL) (absorbance at 340 nm)
Measured: From enrollment to the end of treatment at 32 weeks
Oxidative status
The following markers will be analyzed using spectrophotometry: total antioxidant capacity, TAC (µmol TE/L) (fluoresence).
Measured: From enrollment to the end of treatment at 32 weeks
Anabolic and functional profile
Enzyme-linked immunosorbent assay (ELISA) techniques using validated commercial kits for serum/plasma will be used to analyze: insulin-like growth factor 1, IGF-1 (ng/mL)
Measured: From enrollment to the end of treatment at 32 weeks
Anabolic and functional profile
Enzyme-linked immunosorbent assay (ELISA) techniques using validated commercial kits for serum/plasma will be used to analyze: Myostatin (ng/mL)
Measured: From enrollment to the end of treatment at 32 weeks
Anabolic and functional profile
Enzyme-linked immunosorbent assay (ELISA) techniques using validated commercial kits for serum/plasma will be used to analyze: Testosterone (ng/mL)
Measured: From enrollment to the end of treatment at 32 weeks
Anabolic and functional profile
Enzyme-linked immunosorbent assay (ELISA) techniques using validated commercial kits for serum/plasma will be used to analyze: Vitamin D (ng/mL).
Measured: From enrollment to the end of treatment at 32 weeks
Inflammation markers
Enzyme-linked immunosorbent assay (ELISA) techniques using validated commercial kits for serum/plasma will be used to analyze: α-Klotho (pg/mL)
Measured: From enrollment to the end of treatment at 32 weeks
Inflammation markers
Enzyme-linked immunosorbent assay (ELISA) techniques using validated commercial kits for serum/plasma will be used to analyze: high-sensitivity C-reactive protein, hs-CRP (mg/L).
Measured: From enrollment to the end of treatment at 32 weeks
Quality of life
These will be evaluated using the following questionnaires: SF-12 Health Survey version 2
Measured: From enrollment to the end of treatment at 32 weeks
Cognitive function
These will be evaluated using the following questionnaires: Montreal Cognitive Assessment, (MoCA)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: heart rate, HR (bpm)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: standard deviation of NN intervals, SDNN (ms)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: root mean square of successive differences between NN intervals, RMSSD (ms)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: percentage of NN intervals that differ by more than 50 ms, pNN50 (%)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: low frequency, LF (ms²)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: high frequency, HF (ms²)
Measured: From enrollment to the end of treatment at 32 weeks
Heart rate variability (HRV)
It will be evaluated through continuous heart rate monitoring during training sessions using the H10 POLAR system. Registred in ELITE HRV movil aplication and subsequently, the signals will be analyzed using KUBIOS HRV software to obtain the main heart rate variability (HRV) indicators as a reflection of autonomic modulation. The parameters considered will be: Low Frequency/ High Frequency Ratio(LF/HF ratio).
Measured: From enrollment to the end of treatment at 32 weeks
Internal training load
It will be evaluated through continuous heart rate monitoring during training sessions using the POLAR Team system. Considering the following parameters:
Average and Maximum Heart Rate (Avg HR / Max HR): This indicates the average effort and peak intensity
Measured: From enrollment to the end of treatment at 32 weeks
Internal training load
It will be evaluated through continuous heart rate monitoring during training sessions using the POLAR Team system. Considering the following parameters:
Time in Heart Rate Zones (Zones 1 to 5, defined by Martti Karvonen, Eric Banister and Stephen Seiler)
Measured: From enrollment to the end of treatment at 32 weeks
Internal training load
It will be evaluated through continuous heart rate monitoring during training sessions using the POLAR Team system. Considering the following parameters:
Cardio Load (Cardio Load / TRIMP): This is a numerical value calculated by Polar Team that combines intensity (HR) and session duration.
Measured: From enrollment to the end of treatment at 32 weeks
External training load
The actual mechanical load will be quantified through triaxial accelerometry during training sessions, using accelerometers integrated into monitoring devices (Polar TEAM System) to record: Total Distance Covered: The total volume of the session (in meters or kilometers)
Measured: From enrollment to the end of treatment at 32 weeks
External training load
The actual mechanical load will be quantified through triaxial accelerometry during training sessions, using accelerometers integrated into monitoring devices (Polar TEAM System) to record: Accelerations and Decelerations (Count, (m/s²)
Measured: From enrollment to the end of treatment at 32 weeks
External training load
The actual mechanical load will be quantified through triaxial accelerometry during training sessions, using accelerometers integrated into monitoring devices (Polar TEAM System) to record: Muscle Load. Polar calculates this using accelerometer data (in watts or joules)
Measured: From enrollment to the end of treatment at 32 weeks
External training load
The actual mechanical load will be quantified through triaxial accelerometry during training sessions, using accelerometers integrated into monitoring devices (Polar TEAM System) to record: Speed Zones (Time/Distance in Zones 1 and 2 in Km/h o m/h)
Measured: From enrollment to the end of treatment at 32 weeks
External training load
The actual mechanical load will be quantified through triaxial accelerometry during training sessions, using accelerometers integrated into monitoring devices (Polar TEAM System) to record: Average and Maximum Speed in Km/h o m/h)
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (maximum)
Measured through isometric contraction: Upper limb, handgrip dynamometry, using a dial dynamometer to record the maximal handgrip strength in kilograms.
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (maximum)
Measured through isometric contraction: lower limb, Hawkin Strength platform using an Isometric Test (Half Squat with a strength specific belt). Variables to extract from this test: Absolute Maximal Strength (Peak Force - N): The highest strength recorded during the pull
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (maximum)
Measured through isometric contraction: lower limb, Hawkin Strength platform using an Isometric Test (Half Squat with a strength specific belt). Variables to extract from this test: Relative Maximal Strength (Peak Force Relative - N/kg)
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (maximum)
Measured through isometric contraction: lower limb, Hawkin Strength platform using an Isometric Test (Half Squat with a strength specific belt). Variables to extract from this test: Rate of Force Development in specific time windows (RFD between 0-100 ms and 0-200 ms - N/s): Measures static "explosive strength"
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (maximum)
Measured through isometric contraction: lower limb, Hawkin Strength platform using an Isometric Test (Half Squat with a strength specific belt). Variables to extract from this test: Maximal Strength Asymmetry (%): Indicates whether one lower limb exerts significantly more strength than the other.
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (Power and explosive strength)
Measured through isometric contraction: lower limb, Hawkin Strength platform using a Counter Movement Jump test (CMJ). Variables to extract from this test: Absolute Peak Power (W) and Relative Peak Power (W/kg)
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (Power and explosive strength)
Measured through isometric contraction: lower limb, Hawkin Strength platform using a Counter Movement Jump test (CMJ). Variables to extract from this test: Jump Height (m or cm)
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (Power and explosive strength)
Measured through isometric contraction: lower limb, Hawkin Strength platform using a Counter Movement Jump test (CMJ). Variables to extract from this test: Modified Reactive Strength Index (mRSI or RSImod - AU): Calculated by dividing the jump height by the total time to takeoff.
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (Power and explosive strength)
Measured through isometric contraction: lower limb, Hawkin Strength platform using a Counter Movement Jump test (CMJ). Variables to extract from this test: Propulsion Mean strangth (N or N/kg): The average strength applied to push off the ground
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (Power and explosive strength)
Measured through isometric contraction: lower limb, Hawkin Strength platform using a Counter Movement Jump test (CMJ). Variables to extract from this test: Active Braking / Deceleration Strength (Braking Phase Metrics): Extract the Braking Peak strength
Measured: From enrollment to the end of treatment at 32 weeks
Muscular strength (Power and explosive strength)
Measured through isometric contraction: lower limb, Hawkin Strength platform using a Counter Movement Jump test (CMJ). Variables to extract from this test: • Asymmetry in the Propulsion and Braking Phase (%): Hawkin Dynamics breaks down the imbalances between the left and right leg during each phase of the dynamic movement.
Measured: From enrollment to the end of treatment at 32 weeks
Dynamic Strength Index (DSI)
relationship between explosive (dynamic) strength and theoretical maximal (isometric) strength. It tells us what percentage of their maximal strength the subject is capable of applying quickly.
This variable is derived from Relative Maximal Strength (N/kg) isometric test / Relative Maximal Power (W/kg) from CMJ test.
Measured: From enrollment to the end of treatment at 32 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2026
- Study start20 Oct 2026 (estimated)
- Primary completion20 Jun 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Muscle AdaptationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad Europea de Madrid
- Sponsor type
- University, hospital or other
- Collaborators
- Universidad Politecnica de Madrid, Crown Sport Nutrition
- Responsible party
- Principal investigator, Tamara Iturriaga Ramirez, Universidad Europea de Madrid
- Investigators
- Tamara Iturriaga Ramirez, PhD, Principal investigator, Facultad de Medicina, Salud y Deportes, Departamento de Ciencias del Deporte, Universidad Europea de Madrid
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07891936
- Sponsor's protocol ID
- 2026-1182
- Other IDs
- A027/26
- Acronym
- MyoCreaWalk
- Status last verified
- Oct 2026
- First submitted
- 1 Oct 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Candow DG, Zello GA, Ling B, Farthing JP, Chilibeck PD, McLeod K, Harris J, Johnson S. Comparison of creatine supplementation before versus after supervised resistance training in healthy older adults. Res Sports Med. 2014;22(1):61-74. doi: 10.1080/15438627.2013.852088.
PubMed 24392772Amiri E, Sheikholeslami-Vatani D. The role of resistance training and creatine supplementation on oxidative stress, antioxidant defense, muscle strength, and quality of life in older adults. Front Public Health. 2023 May 2;11:1062832. doi: 10.3389/fpubh.2023.1062832. eCollection 2023.
PubMed 37206869Dobrowolski P, Prejbisz A, Kurylowicz A, Baska A, Burchardt P, Chlebus K, Dzida G, Jankowski P, Jaroszewicz J, Jaworski P, Kaminski K, Kaplon-Cieslicka A, Klocek M, Kukla M, Mamcarz A, Mastalerz-Migas A, Narkiewicz K, Ostrowska L, Sliz D, Tarnowski W, Wolf J, Wylezol M, Zdrojewski T, Banach M, Januszewicz A, Bogdanski P. Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci. 2022 Aug 30;18(5):1133-1156. doi: 10.5114/aoms/152921. eCollection 2022. No abstract available.
PubMed 36160355Chilibeck PD, Kaviani M, Candow DG, Zello GA. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J Sports Med. 2017 Nov 2;8:213-226. doi: 10.2147/OAJSM.S123529. eCollection 2017.
PubMed 29138605Masfiah S, Kurnialandi A, Meij JJ, Maier AB. Definitions of healthspan: A systematic review. Ageing Res Rev. 2025 Sep;111:102806. doi: 10.1016/j.arr.2025.102806. Epub 2025 Jun 14.
PubMed 40523529Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
PubMed 30312372Oudot A, Martin C, Busseuil D, Vergely C, Demaison L, Rochette L. NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. Free Radic Biol Med. 2006 Jun 15;40(12):2214-22. doi: 10.1016/j.freeradbiomed.2006.02.020. Epub 2006 Mar 23.
PubMed 16785035Goddard G, Rajagopal S, Wahbah Makhoul G, Raji MA. Metabolic Syndrome in Older Adults: Through the Lens of Institute for Healthcare Improvement's (IHI) 4Ms Framework and Social Determinants of Health. Life (Basel). 2025 Aug 28;15(9):1370. doi: 10.3390/life15091370.
PubMed 41010311Short KR, Vittone JL, Bigelow ML, Proctor DN, Nair KS. Age and aerobic exercise training effects on whole body and muscle protein metabolism. Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E92-101. doi: 10.1152/ajpendo.00366.2003. Epub 2003 Sep 23.
PubMed 14506079